PM02734

Known as: Depsipeptide PM02734 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2017
02420062017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
This first-in-human, phase I clinical trial was designed to determine the dose-limiting toxicities (DLTs) and the dose for phase… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2013
2013
Elisidepsin (PM02734, Irvalec®) is a synthetic marine-derived cyclic peptide of the Kahalalide F family currently in phase II… (More)
  • table 1
  • figure 1
  • figure 4
Is this relevant?
2012
2012
To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and recommended phase II dose (RD) of elisidepsin… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2012
2012
PM02734 is a chemically synthesized depsipeptide derived from the marine kahalalides family with a broad spectrum of activity… (More)
Is this relevant?
2012
2012
Irvalec® (elisidepsin trifluoroacetate, PM02734) is a novel marine-derived cyclic peptide belonging to the Kahaladide… (More)
  • figure 1
  • figure 2
  • figure 3
  • table I
  • table II
Is this relevant?
2011
2011
PURPOSE PM02734 (elisidepsin) is a synthetic marine-derived cyclic peptide of the kahalalide family currently in phase II… (More)
Is this relevant?
2009
2009
PM02734 (elisidepsin) is a novel marine-derived cyclic peptide belonging to the Kahalalide family of compounds currently under… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2009
2009
2511 Background: PM02734 is a chemically synthesized depsipeptide with a broad spectrum of activity against solid tumors in vitro… (More)
Is this relevant?
2008
2008
PM02734 is a novel synthetic antitumor drug that is currently in phase I clinical trials. To gain some insight into its mode of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2006
2006
A rapid and sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS) assay was developed and validated to quantify a… (More)
Is this relevant?